134 related articles for article (PubMed ID: 11892691)
1. Survival analysis using auxiliary variables via multiple imputation, with application to AIDS clinical trial data.
Faucett CL; Schenker N; Taylor JM
Biometrics; 2002 Mar; 58(1):37-47. PubMed ID: 11892691
[TBL] [Abstract][Full Text] [Related]
2. Survival analysis using auxiliary variables via non-parametric multiple imputation.
Hsu CH; Taylor JM; Murray S; Commenges D
Stat Med; 2006 Oct; 25(20):3503-17. PubMed ID: 16345047
[TBL] [Abstract][Full Text] [Related]
3. Multiple imputation for interval censored data with auxiliary variables.
Hsu CH; Taylor JM; Murray S; Commenges D
Stat Med; 2007 Feb; 26(4):769-81. PubMed ID: 16755528
[TBL] [Abstract][Full Text] [Related]
4. Nonparametric comparison of two survival functions with dependent censoring via nonparametric multiple imputation.
Hsu CH; Taylor JM
Stat Med; 2009 Feb; 28(3):462-75. PubMed ID: 18991250
[TBL] [Abstract][Full Text] [Related]
5. Analysis of accelerated failure time data with dependent censoring using auxiliary variables via nonparametric multiple imputation.
Hsu CH; Taylor JM; Hu C
Stat Med; 2015 Aug; 34(19):2768-80. PubMed ID: 25999295
[TBL] [Abstract][Full Text] [Related]
6. Using cure models and multiple imputation to utilize recurrence as an auxiliary variable for overall survival.
Conlon AS; Taylor JM; Sargent DJ; Yothers G
Clin Trials; 2011 Oct; 8(5):581-90. PubMed ID: 21921063
[TBL] [Abstract][Full Text] [Related]
7. Improving efficiency in clinical trials using auxiliary information: Application of a multi-state cure model.
Conlon AS; Taylor JM; Sargent DJ
Biometrics; 2015 Jun; 71(2):460-8. PubMed ID: 25585942
[TBL] [Abstract][Full Text] [Related]
8. Zidovudine therapy, CD4+ and CD8+ counts are associated with a longer survival following AIDS onset.
Fiala M; Swartz J; Teklehaimanot S; Kermani V; Funnye AS; Sayre JW; Gornbein JA
Lymphology; 1997 Sep; 30(3):128-36. PubMed ID: 9313205
[TBL] [Abstract][Full Text] [Related]
9. A Markov chain Monte Carlo EM algorithm for analyzing interval-censored data under the Cox proportional hazards model.
Goggins WB; Finkelstein DM; Schoenfeld DA; Zaslavsky AM
Biometrics; 1998 Dec; 54(4):1498-507. PubMed ID: 9883548
[TBL] [Abstract][Full Text] [Related]
10. A flexible B-spline model for multiple longitudinal biomarkers and survival.
Brown ER; Ibrahim JG; DeGruttola V
Biometrics; 2005 Mar; 61(1):64-73. PubMed ID: 15737079
[TBL] [Abstract][Full Text] [Related]
11. Modelling progression of CD4-lymphocyte count and its relationship to survival time.
De Gruttola V; Tu XM
Biometrics; 1994 Dec; 50(4):1003-14. PubMed ID: 7786983
[TBL] [Abstract][Full Text] [Related]
12. Using conditional logistic regression to fit proportional odds models to interval censored data.
Rabinowitz D; Betensky RA; Tsiatis AA
Biometrics; 2000 Jun; 56(2):511-8. PubMed ID: 10877311
[TBL] [Abstract][Full Text] [Related]
13. Residuals for proportional hazards models with interval-censored survival data.
Farrington CP
Biometrics; 2000 Jun; 56(2):473-82. PubMed ID: 10877306
[TBL] [Abstract][Full Text] [Related]
14. Phase II, randomized, open-label, community-based trial to compare the safety and activity of combination therapy with recombinant interferon-alpha2b and zidovudine versus zidovudine alone in patients with asymptomatic to mildly symptomatic HIV infection. HIV Protocol C91-253 Study Team.
Krown SE; Aeppli D; Balfour HH
J Acquir Immune Defic Syndr Hum Retrovirol; 1999 Mar; 20(3):245-54. PubMed ID: 10077172
[TBL] [Abstract][Full Text] [Related]
15. A comparison of smoothing techniques for CD4 data measured with error in a time-dependent Cox proportional hazards model.
Bycott P; Taylor J
Stat Med; 1998 Sep; 17(18):2061-77. PubMed ID: 9789914
[TBL] [Abstract][Full Text] [Related]
16. A randomized, controlled, double-blind study comparing the survival benefit of four different reverse transcriptase inhibitor therapies (three-drug, two-drug, and alternating drug) for the treatment of advanced AIDS. AIDS Clinical Trial Group 193A Study Team.
Henry K; Erice A; Tierney C; Balfour HH; Fischl MA; Kmack A; Liou SH; Kenton A; Hirsch MS; Phair J; Martinez A; Kahn JO
J Acquir Immune Defic Syndr Hum Retrovirol; 1998 Dec; 19(4):339-49. PubMed ID: 9833742
[TBL] [Abstract][Full Text] [Related]
17. An evaluation of a measure of the proportion of the treatment effect explained by a surrogate marker.
Bycott PW; Taylor JM
Control Clin Trials; 1998 Dec; 19(6):555-68. PubMed ID: 9875835
[TBL] [Abstract][Full Text] [Related]
18. A comparison of immediate with deferred zidovudine therapy for asymptomatic HIV-infected adults with CD4 cell counts of 500 or more per cubic millimeter. AIDS Clinical Trials Group.
Volberding PA; Lagakos SW; Grimes JM; Stein DS; Rooney J; Meng TC; Fischl MA; Collier AC; Phair JP; Hirsch MS
N Engl J Med; 1995 Aug; 333(7):401-7. PubMed ID: 7616988
[TBL] [Abstract][Full Text] [Related]
19. Relaxing the independent censoring assumption in the Cox proportional hazards model using multiple imputation.
Jackson D; White IR; Seaman S; Evans H; Baisley K; Carpenter J
Stat Med; 2014 Nov; 33(27):4681-94. PubMed ID: 25060703
[TBL] [Abstract][Full Text] [Related]
20. The duration of zidovudine benefit in persons with asymptomatic HIV infection. Prolonged evaluation of protocol 019 of the AIDS Clinical Trials Group.
Volberding PA; Lagakos SW; Grimes JM; Stein DS; Balfour HH; Reichman RC; Bartlett JA; Hirsch MS; Phair JP; Mitsuyasu RT
JAMA; 1994 Aug; 272(6):437-42. PubMed ID: 7913730
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
